Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.

Sharma, Raman; Dowling, Matthew S; Futatsugi, Kentaro; Kalgutkar, Amit S

Sharma, Raman; Dowling, Matthew S; Futatsugi, Kentaro; Kalgutkar, Amit S.

Afiliação

Sharma R; Medicine Design, Pfizer Worldwide Research, Development, and Medical, Eastern Point Road, Groton, Connecticut 06340, United States.
Dowling MS; Medicine Design, Pfizer Worldwide Research, Development, and Medical, Eastern Point Road, Groton, Connecticut 06340, United States.
Futatsugi K; Medicine Design, Pfizer Worldwide Research, Development, and Medical, 1 Portland St, Cambridge, Massachusetts 02139, United States.
Kalgutkar AS; Medicine Design, Pfizer Worldwide Research, Development, and Medical, 1 Portland St, Cambridge, Massachusetts 02139, United States.

Chem Res Toxicol ; 36(6): 934-946, 2023 06 19.

Article em En | MEDLINE | ID: mdl-37148271

Assuntos

Azetidinas; Diacilglicerol O-Aciltransferase; Humanos; Diacilglicerol O-Aciltransferase/metabolismo; Tiazolidinas/metabolismo; NADP/metabolismo; Glutationa/metabolismo; Microssomos Hepáticos/metabolismo; Piperidinas/metabolismo; Azetidinas/farmacologia; Azetidinas/metabolismo; Amidas/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azetidinas / Diacilglicerol O-Aciltransferase Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azetidinas / Diacilglicerol O-Aciltransferase Idioma: En Ano de publicação: 2023 Tipo de documento: Article